Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study

BACKGROUND: Given that memantine is thought to decrease N-methyl-D-aspartic-acid-related (NMDA) glutamatergic hyperactivity and improve locomotion in rats, we sought to assess the drug's impact on axial symptoms in advanced Parkinson's disease (PD). METHODS: We performed a 90-day, randomis...

Descripción completa

Detalles Bibliográficos
Autores principales: Moreau, Caroline, Delval, Arnaud, Tiffreau, Vincent, Defebvre, Luc, Dujardin, Kathy, Duhamel, Alain, Petyt, Gregory, Hossein-Foucher, Claude, Blum, David, Sablonnière, Bernard, Schraen, Susanna, Allorge, Delphine, Destée, Alain, Bordet, Régis, Devos, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2013
Materias:
Movement Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3623038/
https://www.ncbi.nlm.nih.gov/pubmed/23077087
http://dx.doi.org/10.1136/jnnp-2012-303182

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3623038/
https://www.ncbi.nlm.nih.gov/pubmed/23077087
http://dx.doi.org/10.1136/jnnp-2012-303182

Ejemplares similares